With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.02 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $102.41 whereas the lowest price it dropped to was $97.19. The 52-week range on WGS shows that it touched its highest point at $115.60 and its lowest point at $8.63 during that stretch. It currently has a 1-year price target of $107.33. Beta for the stock currently stands at 1.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of WGS was up-trending over the past week, with a rise of 18.92%, but this was up by 8.22% over a month. Three-month performance surged to 41.96% while six-month performance rose 70.37%. The stock gained 962.58% in the past year, while it has gained 33.00% so far this year. A look at the trailing 12-month EPS for WGS yields -1.99 with Next year EPS estimates of 1.89. For the next quarter, that number is 0.08. This implies an EPS growth rate of 248.68% for this year and 112.75% for next year. EPS is expected to grow by 119.03% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 96.65%.
Float and Shares Shorts:
At present, 28.02 million WGS shares are outstanding with a float of 24.53 million shares on hand for trading. On 2025-03-31, short shares totaled 2.76 million, which was 984.0000399999999 higher than short shares on 1740700800. In addition to Ms. Katherine A. Stueland as the firm’s President, CEO & Director, Mr. Kevin Feeley CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.88259006 of WGS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, WGS reported revenue of $95640000.0 and operating income of $8806000.0. The EBITDA in the recently reported quarter was $16344000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for WGS since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With WGS analysts setting a high price target of 135.0 and a low target of 80.0, the average target price over the next 12 months is 107.33333. Based on these targets, WGS could surge 32.07% to reach the target high and fall by -21.74% to reach the target low. Reaching the average price target will result in a growth of 5.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.25799 being high and -$0.2718 being low. For WGS, this leads to a yearly average estimate of -$0.2657. Based on analyst estimates, the high estimate for the next quarter is $0.23 and the low estimate is $0.16. The average estimate for the next quarter is thus $0.2.
